ReSPECT-LMNCT05034497
Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 16 versions: 12 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary completion date changed from estimate of Dec 21, 2025 to Oct 19, 2026 Show 4 more changesShow less
- Eligibility criteria expanded, about 29 words
- Trial completed
- Final enrollment: 37 participants (planned 18)
- Site details revised at 1 of 6 sites
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 6 of 6 sites
- Minor Study sites: 5 to 6v14
- Minor Study sites: 6 to 5v12
- Minor Study sites: 5 to 6v11
Show 6 earlier versionsHide 6 earlier versions
- Minor Study sites: 4 to 5v9
- Minor Study sites: 3 to 4v8
Notable Primary completion date: Jul 30, 2023 to Dec 21, 2025v7 Show 4 more changesShow less
- Eligibility criteria expanded, about 128 words
- Study sites: 2 to 3
- Study completion date: Dec 30, 2023 to Jun 30, 2026
- Study description shortened, about 1 word
- Notable Primary completion date: Jul 30, 2022 to Jul 30, 2023
- Study completion date: Dec 30, 2022 to Dec 30, 2023
- Notable Eligibility criteria expanded, about 20 words
- Site details revised at 2 of 2 sites
Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
- Eligibility criteria expanded, about 23 words
- Study sites: 1 to 2
- Primary completion date: Jun 1, 2022 to Jul 30, 2022
- Study completion date: Aug 30, 2022 to Dec 30, 2022
- Start date changed from estimate of Oct 9, 2021 to Dec 6, 2021
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Incidence and severity of adverse events (AE) and serious adverse events (SAE)
Timeframe: 12 months
Incidence of dose-limiting toxicities (DLT)
Timeframe: 12 months
Secondary (4)
Determination of the overall response rate (ORR)
Determination of the duration of response (DoR)
Determination of progression free survival (PFS)
Overall survival (OS)
Arms and interventions
Dose EscalationExperimental
Each participant will receive a single 5cc administration of 186RNL. At each dose level, a minimum of three to a maximum of six participants will be enrolled. If no dose limiting toxicity is observed in the initial three participants, then the next higher dose level cohort will open for enrollment. The dose escalation scheme will follow a modified Fibonacci dose escalation scheme.
Drugs: 186RNL
Sites
6 sites in 1 country